Health Catalyst, Inc. reported its second-quarter 2025 financial results, with total revenue of $80.7 million and Adjusted EBITDA of $9.3 million, both exceeding quarterly guidance. However, the company significantly revised its full year 2025 guidance downwards.
The full year 2025 total revenue guidance was reduced to approximately $325 million from the previous $335 million, and Adjusted EBITDA guidance was lowered to approximately $35 million from $41 million. This revision reflects increased headwinds, including impacts from Medicaid and research funding cuts affecting large clients.
Additionally, CEO Dan Burton announced his plan to retire effective June 30, 2026, after 15 years of leadership, to pursue service opportunities. He will support the Board in its CEO search and continue to serve on the Board. The company also recognized a goodwill impairment as the fair values of the Technology and Professional Services reporting units were below their carrying values as of June 30, 2025. For the third quarter of 2025, Health Catalyst expects total revenue of approximately $75 million and Adjusted EBITDA of approximately $7 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.